Date,Articles
2014-01-09,"{""abstract"": ""The government has called for a criminal investigation into ads that allegedly used flawed research to promote expanded use of a top-selling drug."", ""web_url"": ""https://www.nytimes.com/2014/01/10/business/international/novartis-faces-possible-criminal-inquiry-in-japan.html"", ""snippet"": ""The government has called for a criminal investigation into ads that allegedly used flawed research to promote expanded use of a top-selling drug."", ""lead_paragraph"": ""TOKYO \u2014 The pharmaceutical company Novartis said Thursday that it would cooperate with the authorities after Japan\u2019s Health Ministry called for a criminal investigation into ads that allegedly claimed additional benefits of its best-selling medicine Diovan based on flawed research."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Novartis Faces Possible Criminal Inquiry in Japan"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Novartis AG"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Clinical Trials"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Crime and Criminals"", ""rank"": 4, ""major"": ""N""}], ""pub_date"": ""2014-01-09T08:39:26+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""subsection_name"": ""International Business"", ""byline"": {""original"": ""By Hiroko Tabuchi"", ""person"": [{""firstname"": ""Hiroko"", ""middlename"": null, ""lastname"": ""Tabuchi"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/0ca8c287-1aa9-57ae-a13b-1e5dece0fa1c"", ""word_count"": 410, ""uri"": ""nyt://article/0ca8c287-1aa9-57ae-a13b-1e5dece0fa1c""}"
2014-03-05,"{""abstract"": ""The Swiss drug companies were ordered to pay a total of $250 million for trying to keep doctors from prescribing a relatively inexpensive eye treatment."", ""web_url"": ""https://www.nytimes.com/2014/03/06/business/international/italy-fines-novartis-and-roche-in-collusion-case.html"", ""snippet"": ""The Swiss drug companies were ordered to pay a total of $250 million for trying to keep doctors from prescribing a relatively inexpensive eye treatment."", ""lead_paragraph"": ""PARIS \u2014 Italian antitrust authorities said on Wednesday that they had fined two Swiss pharmaceutical companies, Novartis and Roche Holdings, a total of $250 million for colluding to keep doctors from prescribing a relatively inexpensive eye treatment in favor of a more expensive drug."", ""print_section"": ""B"", ""print_page"": ""2"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Italy Fines Novartis and Roche in Collusion Case"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""2 Pharmaceutical Makers Fined for Undermining a Rival\u2019s Drug"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 1, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Jolly, David"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Avastin (Drug)"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Novartis AG"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Roche Holding A G"", ""rank"": 5, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""Italy"", ""rank"": 6, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Antitrust Laws and Competition Issues"", ""rank"": 7, ""major"": ""N""}], ""pub_date"": ""2014-03-05T12:33:23+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""subsection_name"": ""International Business"", ""byline"": {""original"": ""By David Jolly"", ""person"": [{""firstname"": ""David"", ""middlename"": null, ""lastname"": ""Jolly"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/68f8e46b-988c-5e1d-bff6-e07e2d2fa17f"", ""word_count"": 818, ""uri"": ""nyt://article/68f8e46b-988c-5e1d-bff6-e07e2d2fa17f""}"
2014-04-07,"{""abstract"": ""Questcor Pharmaceuticals has been criticized for steadily raising the price of its most valuable product, but that aggressive pricing strategy appears to have paid off for the drug maker."", ""web_url"": ""https://dealbook.nytimes.com/2014/04/07/mallinckrodt-to-buy-californias-questcor-for-5-6-billion/"", ""snippet"": ""Questcor Pharmaceuticals has been criticized for steadily raising the price of its most valuable product, but that aggressive pricing strategy appears to have paid off for the drug maker."", ""lead_paragraph"": ""Updated, 8:22 p.m. | Questcor Pharmaceuticals has been criticized for steadily raising the price of its most valuable product \u2014 a 60-year-old immune system drug \u2014 to more than $28,000 a vial from $40 in just a decade. Critics have said the price increases were excessive, and short-sellers have predicted the company\u2019s business and stock price would collapse. "", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/04/08/business/Drug/Drug-jumbo.jpg"", ""height"": 589, ""width"": 589, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/04/08/business/Drug/Drug-superJumbo.jpg"", ""height"": 589, ""width"": 589, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/04/08/business/Drug/Drug-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2014/04/08/business/Drug/Drug-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/04/08/business/Drug/Drug-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Mallinckrodt Pharmaceuticals to Buy Questcor for $5.6 Billion"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Acthar (Drug)"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Autoimmune Diseases"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Boards of Directors"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Federal Taxes (US)"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 6, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Stocks and Bonds"", ""rank"": 7, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Bailey, Don M"", ""rank"": 8, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Barclays PLC"", ""rank"": 9, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Cadence Pharmaceuticals Inc"", ""rank"": 10, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Centerview Partners"", ""rank"": 11, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Chronic Disease Fund"", ""rank"": 12, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Justice Department"", ""rank"": 13, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Latham & Watkins LLP"", ""rank"": 14, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Mallinckrodt Pharmaceuticals"", ""rank"": 15, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Novartis AG"", ""rank"": 16, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Questcor Pharmaceuticals Incorporated"", ""rank"": 17, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Securities and Exchange Commission"", ""rank"": 18, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""WACHTELL LIPTON ROSEN & KATZ"", ""rank"": 19, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""ANAHEIM (CALIF)"", ""rank"": 20, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""California"", ""rank"": 21, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""Dublin (Ireland)"", ""rank"": 22, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""San Diego (Calif)"", ""rank"": 23, ""major"": ""N""}], ""pub_date"": ""2014-04-07T12:33:02+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Andrew Pollack and Chad Bray"", ""person"": [{""firstname"": ""Andrew"", ""middlename"": null, ""lastname"": ""Pollack"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}, {""firstname"": ""Chad"", ""middlename"": null, ""lastname"": ""Bray"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 2}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/c5ff02a5-e175-5e35-8e6a-5e7194cdbf00"", ""word_count"": 719, ""uri"": ""nyt://article/c5ff02a5-e175-5e35-8e6a-5e7194cdbf00""}"
2014-04-22,"{""abstract"": ""William A. Ackman and Valeant are bidding for Allergan, the maker of Botox. | Novartis announced a major overhaul. | AstraZeneca says no to a deal with Pfizer. | Barclays is set to exit its commodities business."", ""web_url"": ""https://dealbook.nytimes.com/2014/04/22/morning-agenda-ackmans-botox-ambitions/"", ""snippet"": ""William A. Ackman and Valeant are bidding for Allergan, the maker of Botox. | Novartis announced a major overhaul. | AstraZeneca says no to a deal with Pfizer. | Barclays is set to exit its commodities business."", ""lead_paragraph"": ""William A. Ackman, one of the brashest men on Wall Street, has come up with perhaps the boldest move yet for an activist: He has teamed up with the health care company Valeant to bid roughly $50 billion for Allergan, the maker of Botox, David Gelles, Michael J. de la Merced and Alexandra Stevenson write in DealBook. The offer by Valeant is expected to be announced Tuesday morning."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Ackman\u2019s Botox Ambitions"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [], ""pub_date"": ""2014-04-22T12:11:47+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Sydney Ember"", ""person"": [{""firstname"": ""Sydney"", ""middlename"": null, ""lastname"": ""Ember"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/4e027bef-017e-5f33-9c69-f72c49d464c2"", ""word_count"": 1946, ""uri"": ""nyt://article/4e027bef-017e-5f33-9c69-f72c49d464c2""}"
2014-04-23,"{""abstract"": ""Pharmaceutical companies are on the prowl for deals. | The Allergan bid charts new territory for takeovers. | Preet Bharara\u2019s perfect record is in jeopardy. | Comcast looks to divest subscribers."", ""web_url"": ""https://dealbook.nytimes.com/2014/04/23/morning-agenda-big-pharmas-deal-bonanza/"", ""snippet"": ""Pharmaceutical companies are on the prowl for deals. | The Allergan bid charts new territory for takeovers. | Preet Bharara\u2019s perfect record is in jeopardy. | Comcast looks to divest subscribers."", ""lead_paragraph"": ""The pharmaceutical industry is regaining its swagger, Michael J. de la Merced, David Gelles and Rachel Abrams write in DealBook. On Tuesday alone, pharmaceutical companies announced $74 billion worth of potential deals, including an unconventional $45.6 billion bid for Allergan, the maker of Botox, and a flurry of swaps and sales between Novartis of Switzerland and GlaxoSmithKline of Britain. More deals in the cash-rich industry are expected."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Big Pharma\u2019s Deal Bonanza"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [], ""pub_date"": ""2014-04-23T11:46:07+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Sydney Ember"", ""person"": [{""firstname"": ""Sydney"", ""middlename"": null, ""lastname"": ""Ember"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/02a31d94-eb4e-5a60-b361-9be61b7fa04d"", ""word_count"": 1881, ""uri"": ""nyt://article/02a31d94-eb4e-5a60-b361-9be61b7fa04d""}"
2014-05-29,"{""abstract"": ""The government says the national health service suffered losses from the drug companies\u2019 efforts to restrict competition in ophthalmic drugs."", ""web_url"": ""https://www.nytimes.com/2014/05/30/business/international/italy-seeks-1-6-billion-in-damages-from-roche-and-novartis.html"", ""snippet"": ""The government says the national health service suffered losses from the drug companies\u2019 efforts to restrict competition in ophthalmic drugs."", ""lead_paragraph"": ""PARIS \u2014 The Italian government is seeking $1.6 billion in damages from two of the world\u2019s biggest drug companies \u2014 Novartis and Roche \u2014 for losses that it says the national health service incurred from the companies\u2019 efforts to restrict competition in ophthalmic drugs."", ""print_section"": ""B"", ""print_page"": ""2"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Italy Seeks $1.6 Billion in Damages From Roche and Novartis"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Novartis and Roche Face Fines in Italy"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""persons"", ""value"": ""Jolly, David"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Novartis AG"", ""rank"": 2, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Pianigiani, Gaia"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Antitrust Laws and Competition Issues"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 6, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""Italy"", ""rank"": 7, ""major"": ""N""}], ""pub_date"": ""2014-05-29T16:26:04+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""subsection_name"": ""International Business"", ""byline"": {""original"": ""By David Jolly and Gaia Pianigiani"", ""person"": [{""firstname"": ""David"", ""middlename"": null, ""lastname"": ""Jolly"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}, {""firstname"": ""Gaia"", ""middlename"": null, ""lastname"": ""Pianigiani"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 2}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/99050c46-617e-5a06-9a52-08fd3ecde0c8"", ""word_count"": 449, ""uri"": ""nyt://article/99050c46-617e-5a06-9a52-08fd3ecde0c8""}"
2014-06-02,"{""abstract"": ""The deal with the biotechnology company Adaptimmune comes a little over a month after Glaxo agreed to sell its cancer drug business to the Swiss pharmaceutical maker Novartis."", ""web_url"": ""https://dealbook.nytimes.com/2014/06/02/glaxosmithkline-in-350-million-cancer-drug-venture/"", ""snippet"": ""The deal with the biotechnology company Adaptimmune comes a little over a month after Glaxo agreed to sell its cancer drug business to the Swiss pharmaceutical maker Novartis."", ""lead_paragraph"": ""LONDON \u2013 Adaptimmune, a biotechnology company, said on Monday that it had reached a deal that could be worth more than $350 million to develop an early stage cancer drug with the pharmaceutical maker GlaxoSmithKline."", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/06/03/business/dbpix-GlaxoSmithKline/dbpix-GlaxoSmithKline-articleLarge.jpg"", ""height"": 401, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2014/06/03/business/dbpix-GlaxoSmithKline/dbpix-GlaxoSmithKline-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 401}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/06/03/business/dbpix-GlaxoSmithKline/dbpix-GlaxoSmithKline-jumbo.jpg"", ""height"": 684, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/06/03/business/dbpix-GlaxoSmithKline/dbpix-GlaxoSmithKline-superJumbo.jpg"", ""height"": 1368, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/06/03/business/dbpix-GlaxoSmithKline/dbpix-GlaxoSmithKline-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2014/06/03/business/dbpix-GlaxoSmithKline/dbpix-GlaxoSmithKline-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/06/03/business/dbpix-GlaxoSmithKline/dbpix-GlaxoSmithKline-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""GlaxoSmithKline in $350 Million Cancer Drug Venture"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Biotechnology"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Cancer"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""GlaxoSmithKline PLC"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Novartis AG"", ""rank"": 6, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""England"", ""rank"": 7, ""major"": ""N""}], ""pub_date"": ""2014-06-02T09:04:35+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Chad Bray"", ""person"": [{""firstname"": ""Chad"", ""middlename"": null, ""lastname"": ""Bray"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/7d47d352-eb38-5874-8cc5-ec0ad240c08a"", ""word_count"": 302, ""uri"": ""nyt://article/7d47d352-eb38-5874-8cc5-ec0ad240c08a""}"
2014-07-09,"{""abstract"": ""An experimental drug for eczema relieved severity of symptoms in 85 percent of those who took it. A drug for psoriasis cut severity of symptoms in as many as 82 percent of those who took it."", ""web_url"": ""https://www.nytimes.com/2014/07/10/business/drugs-show-promise-in-treating-eczema-and-psoriasis-in-trials.html"", ""snippet"": ""An experimental drug for eczema relieved severity of symptoms in 85 percent of those who took it. A drug for psoriasis cut severity of symptoms in as many as 82 percent of those who took it."", ""lead_paragraph"": ""New drugs that block highly specific parts of the immune system are showing remarkable promise in treating two maddening skin diseases, eczema and psoriasis, according to papers published Wednesday in a leading medical journal."", ""print_section"": ""B"", ""print_page"": ""2"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""In Small Trials, 2 Drugs Go Far in Soothing Symptoms of Eczema and Psoriasis"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""In Small Trials, 2 Drugs Go Far in Soothing Symptoms of Eczema and Psoriasis"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""persons"", ""value"": ""Pollack, Andrew"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Enbrel (Drug)"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Skin"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Psoriasis"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Eczema"", ""rank"": 6, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Clinical Trials"", ""rank"": 7, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Novartis AG"", ""rank"": 8, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""New England Journal of Medicine"", ""rank"": 9, ""major"": ""N""}], ""pub_date"": ""2014-07-09T21:53:41+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Andrew Pollack"", ""person"": [{""firstname"": ""Andrew"", ""middlename"": null, ""lastname"": ""Pollack"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/ebba55b2-9e13-559a-b2bb-da8492cc2efc"", ""word_count"": 1039, ""uri"": ""nyt://article/ebba55b2-9e13-559a-b2bb-da8492cc2efc""}"
2014-07-15,"{""abstract"": ""The Alcon unit of the European drug maker will help with one of the latest moves into the health care sector by the tech industry."", ""web_url"": ""https://www.nytimes.com/2014/07/16/business/international/novartis-joins-with-google-to-develop-contact-lens-to-monitor-blood-sugar.html"", ""snippet"": ""The Alcon unit of the European drug maker will help with one of the latest moves into the health care sector by the tech industry."", ""lead_paragraph"": ""LONDON \u2014 Google announced on Tuesday a partnership with the European drug maker Novartis to develop a smart contact lens with the potential to monitor the wearer\u2019s blood sugar levels."", ""print_section"": ""B"", ""print_page"": ""9"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/07/16/business/international/16google-pic/16google-pic-articleLarge.jpg"", ""height"": 400, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2014/07/16/business/international/16google-pic/16google-pic-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 400}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/07/16/business/international/16google-pic/16google-pic-jumbo.jpg"", ""height"": 683, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/07/16/business/international/16google-pic/16google-pic-superJumbo.jpg"", ""height"": 1000, ""width"": 1500, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/07/16/business/international/16google-pic/16google-pic-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2014/07/16/business/international/16google-pic/16google-pic-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/07/16/business/international/16google-pic/16google-pic-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Novartis Joins With Google to Develop Contact Lens That Monitors Blood Sugar"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Novartis Joins With Google to Develop Contact Lens That Monitors Blood Sugar"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Google Inc"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Contact Lenses"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Novartis AG"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Diabetes"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Wearable Computing"", ""rank"": 6, ""major"": ""N""}], ""pub_date"": ""2014-07-15T13:41:38+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""subsection_name"": ""International Business"", ""byline"": {""original"": ""By Mark Scott"", ""person"": [{""firstname"": ""Mark"", ""middlename"": null, ""lastname"": ""Scott"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/49563634-f745-57c8-997c-05bc0a710741"", ""word_count"": 491, ""uri"": ""nyt://article/49563634-f745-57c8-997c-05bc0a710741""}"
2014-08-30,"{""abstract"": ""The experimental drug developed by the Swiss company Novartis reduced the risk of dying from cardiovascular causes and could replace what has been the bedrock treatment for more than 20 years, researchers said."", ""web_url"": ""https://www.nytimes.com/2014/08/31/business/new-novartis-drug-shows-striking-efficacy-in-treating-heart-failure.html"", ""snippet"": ""The experimental drug developed by the Swiss company Novartis reduced the risk of dying from cardiovascular causes and could replace what has been the bedrock treatment for more than 20 years, researchers said."", ""lead_paragraph"": ""An experimental drug has shown a striking efficacy in prolonging the lives of people with heart failure and could replace what has been the bedrock treatment for more than 20 years, researchers said on Saturday."", ""print_section"": ""A"", ""print_page"": ""4"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""New Novartis Drug Effective in Treating Heart Failure"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""New Novartis Drug Effective in Treating Heart Failure"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""persons"", ""value"": ""Pollack, Andrew"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Heart"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Novartis AG"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""New England Journal of Medicine"", ""rank"": 5, ""major"": ""N""}], ""pub_date"": ""2014-08-30T11:00:03+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Andrew Pollack"", ""person"": [{""firstname"": ""Andrew"", ""middlename"": null, ""lastname"": ""Pollack"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/7c7ef98a-4cf9-5643-82e4-d8fe94e84db6"", ""word_count"": 948, ""uri"": ""nyt://article/7c7ef98a-4cf9-5643-82e4-d8fe94e84db6""}"
2015-01-09,"{""abstract"": ""In search of an alternative to hearing aids or implants, some report success in early trials for drugs to improve hearing or silence tinnitus."", ""web_url"": ""https://www.nytimes.com/2015/01/10/business/ear-disorders-long-neglected-attract-drug-makers-attention-.html"", ""snippet"": ""In search of an alternative to hearing aids or implants, some report success in early trials for drugs to improve hearing or silence tinnitus."", ""lead_paragraph"": ""Driving to a meeting in 2008, Jay Lichter, a venture capitalist, suddenly became so dizzy he had to pull over and call a friend to take him to the emergency room."", ""print_section"": ""B"", ""print_page"": ""1"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/01/10/business/10ear-web1/10ear-web1-articleLarge-v2.jpg"", ""height"": 411, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2015/01/10/business/10ear-web1/10ear-web1-articleLarge-v2.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 411}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/01/10/business/10ear-web1/10ear-web1-jumbo-v2.jpg"", ""height"": 702, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/01/10/business/10ear-web1/10ear-web1-superJumbo-v2.jpg"", ""height"": 1405, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/01/10/business/10ear-web1/10ear-web1-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2015/01/10/business/10ear-web1/10ear-web1-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/01/10/business/10ear-web1/10ear-web1-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""From Vertigo to Tinnitus, Ear Ailments Are New Focus for Drugs  "", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Music to the Ears"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Ears and Hearing"", ""rank"": 1, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Pollack, Andrew"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Otonomy Inc."", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Auris Medical Holding A.G."", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Novartis AG"", ""rank"": 6, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Clinical Trials"", ""rank"": 7, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Start-ups"", ""rank"": 8, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Tinnitus"", ""rank"": 9, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 10, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Roche Holding AG"", ""rank"": 11, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""GlaxoSmithKline PLC"", ""rank"": 12, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Avalon Ventures Limited"", ""rank"": 13, ""major"": ""N""}], ""pub_date"": ""2015-01-09T20:31:58+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Andrew Pollack"", ""person"": [{""firstname"": ""Andrew"", ""middlename"": null, ""lastname"": ""Pollack"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/77297f1a-2dbd-57a9-a2e9-8e4a55b021e0"", ""word_count"": 1501, ""uri"": ""nyt://article/77297f1a-2dbd-57a9-a2e9-8e4a55b021e0""}"
2015-06-18,"{""abstract"": ""A federal appeals court on Thursday again invalidated a patent protecting Teva Pharmaceutical\u2019s big-selling drug, Copaxone, which can cost $60,000 a year."", ""web_url"": ""https://www.nytimes.com/2015/06/19/business/ruling-may-clear-way-for-generic-version-of-multiple-sclerosis-drug.html"", ""snippet"": ""A federal appeals court on Thursday again invalidated a patent protecting Teva Pharmaceutical\u2019s big-selling drug, Copaxone, which can cost $60,000 a year."", ""lead_paragraph"": ""The first generic version of a multiple sclerosis drug went on the market Thursday, hours after a federal appeals court again invalidated a patent for the brand-name drug, Copaxone, a major moneymaker for Teva Pharmaceutical."", ""print_section"": ""B"", ""print_page"": ""2"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Teva Ruling Clears Way for Generic Version of Multiple Sclerosis Drug"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Teva Loses Patent Case on Lucrative Multiple Sclerosis Drug"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 1, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Pollack, Andrew"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Generic Brands and Products"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Multiple Sclerosis"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Teva Pharmaceutical Industries Ltd"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Sandoz International GmbH"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Momenta Pharmaceuticals Inc"", ""rank"": 7, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Inventions and Patents"", ""rank"": 8, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Novartis AG"", ""rank"": 9, ""major"": ""N""}], ""pub_date"": ""2015-06-18T18:46:34+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Andrew Pollack"", ""person"": [{""firstname"": ""Andrew"", ""middlename"": null, ""lastname"": ""Pollack"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/6d5e161b-7dfa-5ee8-a06e-1049f0f52138"", ""word_count"": 557, ""uri"": ""nyt://article/6d5e161b-7dfa-5ee8-a06e-1049f0f52138""}"
2015-06-29,"{""abstract"": ""As part of the deal, Celgene will acquire 9.1 million shares of Juno, a leader in cancer drugs that use patients\u2019 immune systems to attack tumors."", ""web_url"": ""https://www.nytimes.com/2015/06/30/business/celgene-to-pay-1-billion-for-biotech-collaboration-with-juno.html"", ""snippet"": ""As part of the deal, Celgene will acquire 9.1 million shares of Juno, a leader in cancer drugs that use patients\u2019 immune systems to attack tumors."", ""lead_paragraph"": ""Celgene, a leading biotech company, said on Monday that it would pay about $1 billion to start a collaboration with Juno Therapeutics, a leader in the hot new area of cancer drugs that harness patients\u2019 immune systems to attack tumors."", ""print_section"": ""B"", ""print_page"": ""3"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/06/30/business/30IMMUNE/30IMMUNE-articleLarge.jpg"", ""height"": 414, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2015/06/30/business/30IMMUNE/30IMMUNE-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 414}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/06/30/business/30IMMUNE/30IMMUNE-jumbo.jpg"", ""height"": 707, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/06/30/business/30IMMUNE/30IMMUNE-superJumbo.jpg"", ""height"": 1330, ""width"": 1927, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/06/30/business/30IMMUNE/30IMMUNE-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2015/06/30/business/30IMMUNE/30IMMUNE-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/06/30/business/30IMMUNE/30IMMUNE-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Celgene to Pay $1 Billion for Biotech Collaboration With Juno"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Celgene to Pay $1 Billion for Juno Collaboration"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Celgene Corporation"", ""rank"": 1, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Pollack, Andrew"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Juno Therapeutics Inc"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Novartis AG"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Biotechnology and Bioengineering"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Cancer"", ""rank"": 6, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Tumors"", ""rank"": 7, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 8, ""major"": ""N""}], ""pub_date"": ""2015-06-29T22:10:30+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Andrew Pollack"", ""person"": [{""firstname"": ""Andrew"", ""middlename"": null, ""lastname"": ""Pollack"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/2edf1930-1b99-5711-92c6-65d435af39b6"", ""word_count"": 708, ""uri"": ""nyt://article/2edf1930-1b99-5711-92c6-65d435af39b6""}"
2015-07-07,"{""abstract"": ""The drug, Entresto, could eventually achieve more than $5 billion in annual sales, said Novartis, which developed it."", ""web_url"": ""https://www.nytimes.com/2015/07/08/business/international/fda-approves-heart-drug-entresto-after-promising-trial-results.html"", ""snippet"": ""The drug, Entresto, could eventually achieve more than $5 billion in annual sales, said Novartis, which developed it."", ""lead_paragraph"": ""The Food and Drug Administration on Tuesday approved a new heart failure drug from Novartis that has been shown to reduce death and hospitalizations from the condition."", ""print_section"": ""B"", ""print_page"": ""3"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""F.D.A. Approves Heart Drug Entresto Said to Cut Death Risk by 20%"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""F.D.A. Approves Drug Said to Cut Death Risk in Heart Patients by 20 Percent"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Heart"", ""rank"": 1, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Pollack, Andrew"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Novartis AG"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Food and Drug Administration"", ""rank"": 5, ""major"": ""N""}], ""pub_date"": ""2015-07-07T22:31:27+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""subsection_name"": ""International Business"", ""byline"": {""original"": ""By Andrew Pollack"", ""person"": [{""firstname"": ""Andrew"", ""middlename"": null, ""lastname"": ""Pollack"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/de9940a5-33f2-5ee5-a6bd-11a492aae9b5"", ""word_count"": 715, ""uri"": ""nyt://article/de9940a5-33f2-5ee5-a6bd-11a492aae9b5""}"
2015-07-29,"{""abstract"": ""The Swiss giant is putting three drugs in development into a new entity backed by investors. With biotech markets hot, there\u2019s room for copycat deals."", ""web_url"": ""https://www.nytimes.com/2015/07/30/business/dealbook/novartis-spinoff-shows-alternative-to-big-drug-makers.html"", ""snippet"": ""The Swiss giant is putting three drugs in development into a new entity backed by investors. With biotech markets hot, there\u2019s room for copycat deals."", ""lead_paragraph"": ""Biotechnology investors can be better than big pharmaceutical companies at valuing and nurturing small drugs. Recognizing this, Novartis is spinning three drugs in development into a new entity backed by British investors. With biotech markets hot, there\u2019s room for copycat deals."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Novartis Spinoff Shows Alternative to Big Drug Makers"", ""kicker"": ""Breakingviews"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Biotechnology and Bioengineering"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Novartis AG"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Mereo BioPharma Group Ltd"", ""rank"": 5, ""major"": ""N""}], ""pub_date"": ""2015-07-29T20:02:16+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""subsection_name"": ""DealBook"", ""byline"": {""original"": ""By Neil Unmack"", ""person"": [{""firstname"": ""Neil"", ""middlename"": null, ""lastname"": ""Unmack"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/311dd382-193d-56c7-b593-181cc1833a79"", ""word_count"": 338, ""uri"": ""nyt://article/311dd382-193d-56c7-b593-181cc1833a79""}"
2015-08-21,"{""abstract"": ""The experimental drug ofatumumab would bolster the Swiss pharmaceutical company\u2019s portfolio of multiple sclerosis treatments."", ""web_url"": ""https://www.nytimes.com/2015/08/22/business/dealbook/novartis-buys-glaxo-drug-for-1-billion.html"", ""snippet"": ""The experimental drug ofatumumab would bolster the Swiss pharmaceutical company\u2019s portfolio of multiple sclerosis treatments."", ""lead_paragraph"": ""Novartis bolstered its portfolio of multiple sclerosis treatments on Friday by agreeing to buy an experimental drug from GlaxoSmithKline for up to $1 billion, the company said."", ""print_section"": ""B"", ""print_page"": ""2"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Novartis to Buy Multiple Sclerosis Drug From Glaxo"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Business Briefing; Novartis Buys Glaxo Multiple Sclerosis Drug"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""persons"", ""value"": ""Tsang, Amie"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 2, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Pollack, Andrew"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""GlaxoSmithKline PLC"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Novartis AG"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Multiple Sclerosis"", ""rank"": 6, ""major"": ""N""}], ""pub_date"": ""2015-08-21T08:39:36+0000"", ""document_type"": ""article"", ""news_desk"": ""Dealbook"", ""section_name"": ""Business Day"", ""subsection_name"": ""DealBook"", ""byline"": {""original"": ""By Amie Tsang and Andrew Pollack"", ""person"": [{""firstname"": ""Amie"", ""middlename"": null, ""lastname"": ""Tsang"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}, {""firstname"": ""Andrew"", ""middlename"": null, ""lastname"": ""Pollack"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 2}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/5ed849e1-1704-5052-bc58-04c6f955c320"", ""word_count"": 528, ""uri"": ""nyt://article/5ed849e1-1704-5052-bc58-04c6f955c320""}"
